Breath for DX

Making every breath count for diagnosis

Breath for DX

New approaches to the respiratory diseases

Establishing Exhaled Breath Aerosol (XBA) sampling for diagnosis and screening of respiratory infections.

Respiratory infections resulted in >7 million deaths in 2020 and were responsible for 7 of the last 9 pandemics, causing trillions of €s in economic losses.

Despite the importance of early detection for individual health and pandemic control, flawed sampling methods for respiratory infections limit the impact of highly-sensitive molecular diagnostics. BreathForDx’s overall goal is to tackle this problem by establishing exhaled breath aerosol (XBA) as a novel, evidence-based sample for respiratory infections in three use cases: diagnosis, screening, and antimicrobial resistance, using tuberculosis (TB) as a model infection.

Breath for DX

workstream & workpackages

The BreathForDx project aims to demonstrate the potential of XBA as a new sample type for airborne pathogens by optimizing and assessing sampling devices, conducting clinical studies, and evaluating large-scale feasibility and population-level impact.

Latest
news

11 November 2024

BreathForDx’ first Annual Consortium Meeting; Milan, 17 September 2024